Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual Meeting - Seite 4

______________________

1. Balyan, R., Ghibellini, G., Sunzel, E. M. et al. (2024). P633 First-in-Human Pharmacokinetic and Safety Study of an Anti-TL1A Antibody, TEV-48574, in Healthy Volunteers and Asthma Patients. Journal of Crohn’s and Colitis, 18(Supplement_1), i1215–i1216. https://doi.org/10.1093/ecco-jcc/jjad212.0763.
2. Raphael, G., Damera. G., Angeles, T. et al. (2024). P1061 TEV-48574, an anti-TL1A antibody in development for use in IBD, is safe and well tolerated following 16 weeks of subcutaneous treatment in adults with severe uncontrolled T2-low/non T2 asthma. Journal of Crohn’s and Colitis, 18(Supplement_1), i1908–i1908. https://doi.org/10.1093/ecco-jcc/jjad212.1191.
3. Reinisch, W., Stoyanov, S., Raphael, G. et al. (2024). P998 Phase 2 basket design study evaluating the efficacy and safety of an anti-TL1A antibody (TEV-48574) in moderate to severe ulcerative colitis or Crohn’s Disease (RELIEVE UCCD). Journal of Crohn’s and Colitis, 18(Supplement_1), i1811–i1811. https://doi.org/10.1093/ecco-jcc/jjad212.1128.
4. Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment. https://ir.tevapharm.com/news-and-events/press-releases/press-release- .... Accessed Feb 2024.
5. What is inflammatory bowel disease (IBD)? Centers for Disease Control and Prevention. 2022. Available at: https://www.cdc.gov/ibd/what-is-IBD.htm. Accessed Feb 2024.
6. McDowell, C., Farooq, U., & Haseeb, M. (2020). Inflammatory Bowel Disease (IBD). PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK470312/.
7. Dharni, K., Singh, A., Sharma, S. et al. Trends of inflammatory bowel disease from the Global Burden of Disease Study (1990-2019). Indian Journal of Gastroenterology (2023). https://doi.org/10.1007/s12664-023-01430-z.
8. A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease (RELIEVE UCCD) https://clinicaltrials.gov/study/NCT05499130?term=TEV-48574&rank=2. Accessed Feb 2024.
9. A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease. https://clinicaltrials.gov/study/NCT05668013?term=TEV-48574&rank=1. Accessed Feb 2024.